Scroll Up
Scroll Down
Play Play Play Play
Unregistered User
Click here if this is not your Personal Edition
 
Contact Us | Free E-Mail Updates | Journals | Register a colleague
 
 
Angina Pectoris/MI
 
   
 
SEARCH   
Doctor's Guide Free CME
Medline
Congress Resource Centre
 

 EXPLORE :
   Most Read News
 All News  All News
 All Webcasts / CME  All Webcasts / CME
 All Cases  All Cases
 Congress Resource Centre  Congress Resource Centre
 All Medical Resources  All Medical Resources
 Medical  My Personal Edition



Warning | Privacy

 

 
 Recent news - Angina Pectoris/MI
    Early invasive vs conservative treatment strategies in women and men with unstable angina and non-ST-segment elevation myocardial infarction: a meta-analysis - (JAMA)
    Invasive Treatment Appears Beneficial for Men and High-Risk Women With Certain Coronary Syndromes - (DGNews)
    Outcomes following coronary stenting in the era of bare-metal vs the era of drug-eluting stents - (JAMA)
    New Guidance Available for Cardiologists Treating Myocardial Bridging - (DGNews)
    TopAbstracts in Angina Pectoris/MI 06/25/2008 - (DGNews)

    News archive

     Recent webcasts/CME - Angina Pectoris/MI
      Optimizing Antiplatelet Therapy in the ACS Patient: The Intersection of Acute Coronary Syndromes and Oral Antiplatelet Therapy
      Use of Direct Thrombin Inhibitors for Treating Non-St-Segment Elevation Acute Coronary Syndromes in Special Patient Groups: Women, Diabetics, the Elderly, and Chronic Renal Insufficiency
      CRUSADE: Contemporary Evaluation and Management of 200,000 High-Risk NSTE-ACS Patients
      Understanding Chronic Ischemic Heart Disease Today
      Risk Stratification in Patients with Chronic Myocardial Ischemia

      Webcasts/CME archive

       Recent cases - Angina Pectoris/MI
        Diagnostic Uncertainty of Takotusbo Cardiomyopathy Presenting as Acute Myocardial Infarction in a Woman with Cardiovascular Risk Factors Hijacked at Gunpoint: A Case Report
        The Role of Intravascular Ultrasound in the Management of Spontaneous Coronary Artery Dissection
        Unusual Cause of Exercise-Induced Ventricular Fibrillation in a Well-Trained Adult Endurance Athlete: A Case Report
        Myocardial Ischemia in the Absence of Epicardial Coronary Artery Disease in Friedreich's Ataxia
        Double Rupture of Interventricular Septum and Free Wall of the Left Ventricle, as a Mechanical Complication of Acute Myocardial Infarction: A Case Report

        Cases archive
          




        my personal edition > angina pectoris/mi > news
        divider

          E-Mail this DGNews to a colleague

        DGNews


        ERICA Trial Results Showing Ranolazine Extended-Release Tablets Reduce Angina Frequency and Nitroglycerin Consumption

        PALO ALTO, CA -- June 19, 2006 -- CV Therapeutics, Inc. announced today that the Journal of the American College of Cardiology (JACC) has published data from the Efficacy of Ranolazine In Chronic Angina (ERICA) trial. In the ERICA trial, Ranexa(R) (ranolazine extended-release tablets) significantly reduced angina frequency (P =.028) and nitoglycerin consumption (P =.014) in angina patients compared to placebo.

        Forty-five percent of patients in the study were on concomitant long acting nitrates. Ranexa was well tolerated and there were no observed differences in the frequency of serious adverse events between Ranexa and placebo.

        "Angina places a tremendous burden on patients, their families and the healthcare system, and the results of the ERICA study highlight how ranolazine could benefit a portion of this population," said Peter Stone, MD, lead author of the publication and co-director, Samuel A. Levine Cardiac Unit, Brigham and Women's Hospital in Boston. "Ranolazine represents the first new pharmaceutical approach in decades for physicians to consider in treating appropriate angina patients."

        Ranexa is approved in the United States as a second-line treatment for chronic angina and has antianginal and anti-ischemic effects that do not depend upon reductions in heart rate or blood pressure. Ranexa should be used in combination with amlodipine, beta-blockers or nitrates. According to the approved labeling, because Ranexa prolongs the QT interval, it should be reserved for patients who have not achieved an adequate response with other antianginal drugs. The effect on angina rate or exercise tolerance appeared to be smaller in women than men.

        The ERICA study was published online by JACC and is expected to be included in a future print edition of JACC. An editorial from John Cairns, MD, professor of cardiology at the University of British Columbia in Vancouver, accompanies the publication.


        SOURCE: CV Therapeutics, Inc.



        E-Mail this DGNews to a colleague   To print, use this version






        All contents Copyright (c) 1995-2008 Doctor's Guide Publishing Limited. All rights reserved.



        The NTK initiative. Physicians helping physicians identify Need-To-Know science
           Feedback
        Please rate this article: Strongly DISAGREE...Strongly AGREE NTK logo
        Question 1 - Physicians need to become aware of this information as soon as possible. Question 2 - This information is likely to have an impact on the way physicians practice medicine.
        1
        2
        3
        4
        5
        6
        7
        Send